Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohide Tamura

Showing results (21-30 of 263) with videos related to

Pageof 27
Sort By:
Japanese Journal of Clinical Oncology|June 30, 2007
Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature reviewIkuo Sekine, John D Minna, Kazuto Nishio, et al.
Cancer Science|December 15, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft modelsFumiko Taguchi, Yasuhiro Koh, Fumiaki Koizumi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2009
Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV diseaseIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Science|May 15, 2007
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptorHideharu Kimura, Kazuko Sakai, Tokuzo Arao, et al.
Investigational New Drugs|June 10, 2010
Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal disseminationFumiko Taguchi, Yasuo Kodera, Yasufumi Katanasaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Current Status of Single-Agent Phase I Trials in Japan: Toward GlobalizationHidenori Mizugaki, Noboru Yamamoto, Yutaka Fujiwara, et al.
Cancer Research|December 18, 2004
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474Tokuzo Arao, Hisao Fukumoto, Masayuki Takeda, et al.
Cancer Science|August 7, 2003
Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)Yuichiro Ohe, Naoki Ishizuka, Tomohide Tamura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2018
Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic FindingsRyosuke Imai, Masafumi Ono, Naoki Nishimura, et al.
Japanese Journal of Clinical Oncology|February 6, 2010
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumorsKazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, et al.
Pageof 27

Showing results (21-30 of 263) with videos related to

Sort By:
Pageof 27
Japanese Journal of Clinical Oncology|June 30, 2007
Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature reviewIkuo Sekine, John D Minna, Kazuto Nishio, et al.
Cancer Science|December 15, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft modelsFumiko Taguchi, Yasuhiro Koh, Fumiaki Koizumi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2009
Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV diseaseIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Science|May 15, 2007
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptorHideharu Kimura, Kazuko Sakai, Tokuzo Arao, et al.
Investigational New Drugs|June 10, 2010
Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal disseminationFumiko Taguchi, Yasuo Kodera, Yasufumi Katanasaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Current Status of Single-Agent Phase I Trials in Japan: Toward GlobalizationHidenori Mizugaki, Noboru Yamamoto, Yutaka Fujiwara, et al.
Cancer Research|December 18, 2004
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474Tokuzo Arao, Hisao Fukumoto, Masayuki Takeda, et al.
Cancer Science|August 7, 2003
Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)Yuichiro Ohe, Naoki Ishizuka, Tomohide Tamura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2018
Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic FindingsRyosuke Imai, Masafumi Ono, Naoki Nishimura, et al.
Japanese Journal of Clinical Oncology|February 6, 2010
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumorsKazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, et al.
Pageof 27